Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of eribulin in combination with carboplatin
and trastuzumab in the neoadjuvant setting in subjects who are human epidermal growth factor
receptor (HER)2 positive and are clinically stage IIA to IIIB.
The study regimen will be administered every 3 weeks for a total of 6 cycles followed by
definitive surgery.